|
Quotient Limited (NASDAQ: QTNT) |
|
Quotient Limited
QTNT's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Quotient Limited's sales fell
by -4.4 % in III. Quarter 2022 from the same quarter a year ago.
Ranking at No. 3097
In Vitro & In Vivo Diagnostic Substances industry recorded
growth of revenues by 84.1 %
Quotient Limited net loss decreased from $-27 millions, to $-13 millions in III. Quarter 2022,
• More on QTNT's Growth
|
|
Quotient Limited realized a net loss in trailing twelve months.
Quotient Limited realized cash reduction of $ -27.4 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.04.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 6.72.
• More on QTNT's Valuation
|
|
|
|
|
Quotient Limited realized net loss in trailing twelve months.
Quotient Limited realized cash outflow of $ -27.4per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 0.04.
In Vitro & In Vivo Diagnostic Substances industry's Price to Sales ratio is at 6.72.
• More on QTNT's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com